Skip to main content
Smart Investors Daily
AL

NYSE · ALC

Alcon Inc.

Healthcare · Medical - Instruments & Supplies

$75.26

Down-$0.76 (-1.01%)

Updated Nov 20, 2026, 1:15 AM

SID Score

6.2/10

Composite research score

Smart Money

48/100

Neutral

Market cap
42.99B
P/E ratio
43.53
Dividend yield
0.44%
52-week range
$61.84 – $87.64
Volume
4.77M
Avg. volume
1.54M

Price performance · ALC

ALC price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 18, 2026

ALC closed at $75.26 after 20 trading sessions, up 6.56% for the selected period.

Last close
$75.26
Period change
+6.56%
Period low
$69.42
Period high
$77.31
Daily close
View OHLC price history
ALC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 18, 2026$73.41$75.52$73.34$75.264.77M
Nov 17, 2026$73.405$74.54$73.36$74.114.8M
Nov 16, 2026$74.35$74.76$73.495$73.641.77M
Nov 13, 2026$72.97$74.18$72.575$74.122.79M
Nov 12, 2026$73.06$73.955$71.64$71.832.25M
Nov 11, 2026$71.70$72.535$70.34$72.464.87M
Nov 10, 2026$74.72$75.705$72.21$74.065.33M
Nov 9, 2026$74.62$75.49$74.28$75.142.82M
Nov 6, 2026$74.24$75.23$74.01$74.943.17M
Nov 5, 2026$77.17$77.825$76.185$76.552.63M
Nov 4, 2026$75.70$77.85$75.58$77.313.75M
Nov 3, 2026$73.04$73.24$72.345$72.371.92M
Nov 2, 2026$72.06$74.19$72.03$73.632.2M
Oct 30, 2026$72.34$72.715$71.27$71.451.61M
Oct 29, 2026$70.44$71.35$70.39$71.131.26M
Oct 28, 2026$68.875$70.08$68.82$69.831.09M
Oct 27, 2026$69.58$70.02$69.30$69.421.2M
Oct 26, 2026$70.08$70.45$69.70$69.991.46M
Oct 23, 2026$70.16$70.46$69.54$70.172.59M
Oct 22, 2026$68.02$70.68$67.96$70.632.21M

Latest ALC news

The latest Smart Investors Daily articles mentioning ALC.

ALC research

Overview

Company profile and research snapshot.

Company profile

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$92.35
Implied upside
—
Analysts
6
ALC recent ratings
DateFirmRatingTarget
Sep 21, 2026BERENBERGBuy—
Aug 31, 2026BNP PARIBASNeutral—
Aug 14, 2026EQUITA SIMBuy—
Aug 11, 2026NEEDHAM & COMPANY INC.Buy—
Jul 20, 2026DAY BY DAYSell—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 12, 2026

Are Q3 Results Altering The Investment Case For Alcon (SWX:ALC)?

Alcon reported Q3 2026 revenue of US$2.74b and net income of US$260 million, alongside a revised full year 2026 net sales growth outlook of about 6%. The business is relying more on Surgical equipment and Vision Care momentum. At the same time, U.S. premium IOL competition and slightly tighter earnings guidance highlight pressure on higher value lenses. The focus now turns to how Alcon's premium mix and margin profile could be influenced by firmer overall sales and softer premium IOL...

Yahoo · Nov 12, 2026

Alcon (SWX:ALC) Stock Could Be 47% Undervalued After Neurotech Acquisition

Alcon has delivered mixed share performance in recent years, and the question for you now is whether the current price lines up with what its cash flows can support. With fresh product approvals and an acquisition reshaping its eye care portfolio, the stock invites a closer look at what the underlying business is really worth on a cash flow basis. Over the past 5 years the share price has fallen 21.9%, which puts sharper focus on whether the cash the business can generate justifies where the...

Yahoo · Nov 12, 2026

What Could Alcon (SWX:ALC) Q3 Sales And New Deal Mean For Growth?

Alcon (SWX:ALC) reported strong Q3 2026 sales performance, underscoring momentum in its core eye care operations. The firm received US FDA approvals for new intraocular lens products intended for use in cataract and vision correction procedures. Management broadened the portfolio with the acquisition of Neurotech Pharmaceuticals, adding drug delivery capabilities in ophthalmology. The Q3 sales update and Neurotech Pharmaceuticals deal matter. However, investors should weigh more than this...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.